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There is good evidence that the major pathological manifestations of systemic 
lupus erythematosus (SLE)' are related to the occurrence of immune complexes 
in blood or in tissues.  Circulating  immune  complexes have been detected by 
various methods in serum from patients with SLE (1-4) and immune complexes 
localized in tissues have been demonstrated by immunofluorescence and elec- 
tron microscopic studies (5-9). 
The  development  of the  acute  clinical  manifestations  of SLE  is  generally 
associated with the presence in serum of a high titer of anti-DNA antibodies (10- 
12), and immune complexes formed of DNA, and anti-DNA antibodies have been 
shown to be the major component of the immune complexes localized in renal 
and skin lesions (11,  13, 14). However, such DNA-anti-DNA complexes seem to 
represent  only a  very small  portion  of the  complexes detected in  circulating 
blood (3). Therefore,  one may wonder whether the tissue localization of DNA- 
anti-DNA  complexes results  directly from the localization  of circulating  com- 
plexes,  as in serum sickness,  or whether other mechanisms  are involved. The 
latter hypothesis is also suggested by the fact that in many of the patients with 
SLE, the initial manifestations  may be represented by only one type of lesion, 
such  as  a  limited  skin  disease,  with  delayed  appearance  of other  systemic 
manifestations. 
The present investigation has been undertaken to define some of the factors 
which may favor the deposition or the local formation of DNA-anti-DNA com- 
plexes in tissue structures where such complexes are commonly localized during 
the course of SLE. In particular,  the frequent concentration of DNA-anti-DNA 
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complexes at the surface or inside basement membranes in kidney and in skin 
lead us to consider the possibility that basement membranes have a particular 
affinity for such DNA-anti-DNA complexes. 
It  was found  that  in  vitro  DNA  alone  can  be efficiently bound to isolated 
glomerular basement membranes (GBM) and, in more general terms, to struc- 
tures containing collagen. This GBM- or collagen-bound DNA can subsequently 
react  with  anti-DNA  antibodies  and  form  immune  complexes  which  remain 
localized on these structures.  Inversely, preformed DNA-anti-DNA complexes 
are not efficiently bound by GBM or collagen. These in vitro observations raise 
again the possibility that the systemic character of SLE might be partly related 
to the widespread distribution of collagen or collagen-like structures  as previ- 
ously proposed by Klemperer  (15). 
Materials  and  Methods 
DNA.  Highly polymerized calf thymus DNA (type V, Sigma Chemical Co., St. Louis, Mo.) 
was  used  without  further  purification.  Mouse  kidney  DNA,  bacterial  DNA from Micrococcus 
lysodeikticus,  viral DNA from SV 40, and plant DNA from tobacco purified by Marmur's technique 
(16) were kindly provided by Dr. Ttirler (Department of Molecular Biology, University of Geneva). 
Denatured  DNA was prepared by heating native DNA (0.5  mg/ml in phosphate-buffered  saline 
[PBS],  pH  7.0)  at  100°C  for  10  min,  followed by immediate cooling in  an  ice bath.  DNA was 
fractionated on methylated albumin kieselguhr (MAK) columns according to Sueoka and Cheng 
(17) to separate double-stranded  DNA (DSDNA) from single-stranded  DNA (SSDNA). DSDNA 
was eluted with NaC1 gradient of 0.5-0.9 M buffered with 0.05 M PO4, pH 6.7,  while SSDNA was 
eluted with 1.0 M NaCl-l.5 M NH4OH. DNA fractions eluted from the column were immediately 
dialyzed against borate buffer (ionic strength 0.1,  pH 8.4). 
Proteins,  Lipopolysaccharides  and Antisera.  Bovine serum albumin  (BSA) and methylated 
BSA (mBSA) were obtained  from Calbiochem,  San  Diego,  Calif.  Bacterial  lipopolysaecharides 
(LPS) from Salmonella typhimurium (lot 563628), Escherichia  coli 0127:B8 (lot 582337), andE. coli 
0111:B4  (lot 587687)  were  obtained  from Difco Laboratories,  Detroit,  Mich.  They were further 
purified  by  the  phenol-water  extraction  method,  followed by  fractionation  with  ethanol  and 
ultracentrifugation  (18). Human IgG (HGG) was prepared by chromatography through a DEAE- 
cellulose column equilibrated with 0.01  M phosphate buffer at pH 8.0.  Human C{q component of 
complement was prepared from fresh human serum according to Yonemasu and Stroud (19). 
Normal mouse serum (NMS) was collected from 6 to 10-wk-old C57BL/6 mice, purchased from 
Charles  River Breeding  Laboratories,  Inc.,  Elbeuf,  France.  Anti-DNA antisera  were obtained 
from mice immunized with DNA-mBSA complexes as described previously (20), or NZB x  NZW F, 
hybrid mice. NZB and NZW mice were originally provided by Dr. F. Dixon from the Scripps Clinic 
and Research Foundation, La Jolla, Calif., and inbred in our own animal house. Sera were stored 
at -20°C until used except when fresh serum was needed. 
GBM and Collagen.  GBM was isolated from normal human kidneys obtained from autopsies. 
The  isolation  of glomeruli  was  based  on  the  method  of Krakower  and  Greenspon  (21) using 
stainless steel sieves and repeated sedimentation in 0.15 M NaC1 until the materials on the sieves 
contained practically pure  glomeruli as checked by light microscopy.  GBM was obtained  from 
these isolated glomeruli by ultrasonic disruption (MSE sonicator, Measuring & Scientific Equip- 
ment  Ltd.,  Sussex,  England),  conducted  until  complete  fragmentation  of the  giomeruli.  The 
sonicated materials were washed five times with 0.15 M NaCI at 3,000 rpm. The sediments were 
used as GBM. 
Type I collagen purified from calf skin,  and type III collagen from fetal calf skin were kindly 
provided by Dr.  C. M. Lapi~re (Clinique dermatologique,  Universit$ de Liege, Belgium). These 
collagen preparations were solubilized with 0.1 M acetic acid at 4°C for 24 h. The soluble collagen 
obtained was dialyzed against potassium phosphate buffer, pH 7.6,  at 4°C for 24 h, then dialyzed 
against 0.15  M NaC1 at 4°C for 24 h. Insoluble collagen was prepared by incubating the soluble 
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bovine achilles tendon was purchased from Sigma Chemical Co. The protein concentration was 
determined by the method of Lowry et al. (22). Insoluble GBM and collagen were solubilized with 
0.1 N  NaOH for the determination of protein concentration. 
Radiolabeling Procedures.  DNA was labeled either externally with iodine (~2sI), or internally 
with tritium (3H). Iodination of DNA was carried out according to the method of Commerford (23). 
[3H]DNA was prepared from human fibroblasts L~32 grown in culture in presence of [3H]thymidine. 
DNA was isolated by Marmur's technique (16).  These DNA preparations were shown to contain 
less than 1% of Pronase-sensitive material. These radiolabeled DNA were fractionated on MAK 
columns to obtain pure double-stranded and single-stranded forms. To remove selectively single- 
stranded  regions  within  DSDNA,  [12~I]DSDNA  was  treated  with  single-stranded  specific  $1 
nuclease (Seikagaku Kogyo, Tokyo, Japan) in some experiments. The reaction mixtures consisted 
of 1/~g of [~2SI]DSDNA and 2,000 U of S1 nuclease in 1.5 ml of 0.1 M KC1,  0.1 mM ZnSO4, 0.025 M 
sodium acetate, pH 4.5. Incubation was at 37°C for 2 h. 
HGG and BSA were labeled with iodine (;2sI or ;31I) according to the procedure of McConahey 
and Dixon (24). The labeling of LPS with s~Cr was carried out according to the method of Braude et 
al.  (25). 
Binding Assay.  The  binding of radiolabeled preparations to  insoluble  GBM and  insoluble 
collagen  was  assayed  using  the  following  procedures:  various  amounts  of insoluble  GBM  or 
collagen suspended in 0.1 ml of 0.15 M NaC1 were incubated with 0.1 ml of radioactive prepara- 
tions in  the presence  of 0.1  ml  of 10%  heat-inactivated NMS  at  4°C  overnight with constant 
shaking. As a control, radiolabeled preparations were incubated with NMS alone. All the reaction 
mixtures were centrifuged at  1,000 g  for 20 rain,  then washed twice with PBS.  Iodine-labeled 
preparations precipitated were directly counted in an automatic Beckman gamma counter (Beck- 
man Instruments, Inc, Palo Alto, Calif.). The specific amount of radioactive preparations bound 
to GBM or collagen was obtained by subtracting the counts per minute in the control tubes from 
the counts per minute in the experimental tubes. The results were expressed as a  percentage of 
radiolabeled preparations specifically bound to GBM or collagen. For [3H]DNA, the supernatant 
from the reaction mixtures was transferred into 15 ml of Dioxan scintillation fluid for counting in 
an LS 250 Beckman liquid scintillation counter. 
Inhibition of the binding of ;25I-labeled calf thymus DNA to the insoluble GBM or collagen by 
unlabeled  DNA  was  studied  by  incubating  various  concentrations of unlabeled  DNA  with  a 
constant amount of [~2SI]DNA and GBM or collagen. Inhibition studies with anti-DNA antisera, 
fresh NMS, or Clq were conducted according to the same procedure. 
The  effect  of pH  on  the  binding  of  DNA  to  GBM  was  investigated  as  follows:  50  ng  of 
[;25I]SSDNA in 0.01 ml of distilled water was incubated with 300 ~tg of GBM in 0.05 ml of distilled 
water containing 2% BSA in the presence of 0.2 ml of Britten-Robinson buffer at pH 3, 5, 7, 9, and 
11. As control,  [~2sI]SSDNA  was incubated alone with distilled water containing 2% BSA at the 
different pH values. The specific precipitation of [~2sI]SSDNA  was calculated for the different pH 
values described above.  The  effect of the salt concentration was  studied  as  follows:  0.2  ml  of 
various concentrations (0.01-2.0  M)  of NaC1  was  added to  [;2sI]SSDNA and GBM mixtures  as 
described in the above procedure instead of using Britton-Robinson buffer. 
The binding of [;25I]DNA  and [~2~I]BSA to the soluble collagen was assayed by precipitation of 
[;25I]DNA  protein or p2SI]BSA protein complexes with 10% polyethylene glycol (PEG),  in which 
free radiolabeled DNA and BSA were soluble (26), while the soluble collagen was precipitated. 10 
ng of radiolabeled preparations were incubated with 100  /~g of soluble collagen (type I) in the 
presence of 10% heat-inactivated NMS at 37°C for 2 h. The mixtures were treated with PEG (final 
concentration: 10%) and incubated at 4°C overnight. The precipitates were centrifuged at 1,000 g 
for 30 rain, then washed with 10% PEG. The results were expressed as a percentage of radiolabeled 
preparations specifically precipitated. The specific precipitation of radiolabeled preparations was 
calculated after correction for the nonspecific precipitation obtained in the presence of 10% heat- 
inactivated NMS. The formula described by Farr (27) was used for this correction. 
CoUagenase Digestion of GBM.  Collagenase from Colstridium  histolyticurn (type III, fraction 
A, 460 U/rag) was obtained from Sigma Chemical Co.  A  1-mg/ml solution was prepared in 0.1 M 
Tris-acetate buffer, pH 7.4.  For digestion of GBM with collagenase,  150 /~g of GBM in 0.1 ml of 
Tris-acetate buffer was incubated with 100 ~tg of collagenase for 12 h at 37°C. The enzyme reaction 
was stopped by cooling in an ice bath.  As undigested control,  GBM was incubated with buffer 
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Elution of  Anti-DNA Antibodies.  Elution of anti-DNA antibodies from GBM-DNA-anti-DNA 
mixtures was carried out as follows: 300 ~g of GBM was incubated with 100 ~g of DNA or PBS 
overnight at 4°C, then washed three times with PBS. 0.1 ml of heat-inactivated anti-DNA antisera 
or NMS was added and incubated overnight at 4°C, then washed three times with Veronal buffer 
pH 7.2. These mixtures were treated with 0.1 ml of 1 mg/ml DNase (deoxyribonuclease  I, 2,600 U/ 
mg, Worthington Biochemical Corp., Freehold, N. J,) in Veronal buffer at 37°C for 12 h to elute 
anti-DNA antibodies (11). 0.05 ml of 0.03 M EDTA was added to inhibit the DNase activity. The 
eluates obtained were examined for DNA-binding activity by a modification of the Farr test (28). 
0.025 ml of eluates was incubated in 0.1 ml of 10 ng of [!~sI|SSDNA in the presence of 0.1 ml of 10% 
heat-inactivated NMS. The radioactivity of [I~sI]SSDNA  precipitated with 50% saturated ammo- 
nium sulfate was measured in a gamma counter, and the results were expressed as a percentage of 
[12~I]SSDNA precipitated. 
Intravenous  Injection  of Radiolabeled  Preparations  to Mice.  5.0 ~g of ~SI-labeled SSDNA and 
~I-labeled BSA in 0.2 ml saline was injected to normal C57BL/6  female mice and to similar mice 
previously injected with 100  ~g of S. typhimurium  LPS.  The amounts of injected radiolabeled 
preparations in kidneys and liver were calculated from radioactivity measurement. The results 
were expressed as the absolute amounts of injected SSDNA or BSA per gram of organ. 
Results 
Binding of DNA to GBM.  Various sources of DNA, HGG, BSA, and bacte- 
rial  LPS were  tested for the binding to  GBM.  125I-labeled SSDNA  from calf 
thymus, mouse kidneys, bacteria  (M.  lysodeikticus),  virus  (SV40) and plant 
(tobacco),  125I-labeled DSDNA  from calf thymus and 3H-labeled SSDNA  and 
DSDNA from human fibroblasts were used. 50 ng of each of these radiolabeled 
preparations was incubated with 300 ~g of sonicated fragments of human GBM 
suspended in 10% heat-inactivated NMS. As a control, these radiolabeled prepa- 
rations were incubated with NMS alone. All the preparations of DNA used were 
significantly bound by GBM, 40-80 times more than HGG and BSA, and 10-40 
times more than LPS (Table I).  After treatment of [~2SI]DSDNA with S1  nu- 
clease to selectively remove single-stranded regions within DSDNA, there was 
no significant difference in the binding to GBM as compared with nontreated 
[125I]DSDNA (S1 treated: 36.6_+2.6%, nontreated: 40.6_+2.7%). 
The possibility that DNA or basic nuclear proteins, such as histones, contami- 
nating the GBM preparations could be involved in the binding of DNA to GBM 
was investigated. GBM pretreated with DNase at 37°C for 12 h  or with 2.0  M 
NaC1 at 4°C for 18 h (29) showed a higher DNA-binding activity (DNase-digested 
GBM: 32.4_+4.4%; 2.0 M NaCl-treated GBM: 36.3_+4.2%) than nontreated GBM 
(26.8_+1.8%). 
Increasing amounts (0.01-100  ~g) of unlabeled calf thymus DNA were added 
to 100 ~g of GBM with 5 ng of 125I-labeled calf thymus DNA. There was a linear 
inhibition of the binding of [12~I]SSDNA in the presence of unlabeled SSDNA 
(Fig. la). 7 ~g of unlabeled SSDNA was needed to obtain a 50% inhibition of the 
binding of 5 ng of [~25I]SSDNA. Only a very high concentration of DSDNA could 
inhibit the binding of [~25I]SSDNA. On the other hand, only 0.35 ~g of SSDNA 
or  DSDNA  was  sufficient  to  obtain  a  50%  inhibition  of  the  binding  of 
[12SI]DSDNA (Fig. lb). 
The maximum amounts of SSDNA and DSDNA, which can be bound to GBM, 
were  determined by incubating a  constant amount of GBM with increasing 
amounts of DNA. At saturation, approximately 4.0 ~g of SSDNA and 0.5 ~g of 
DSDNA were bound per 100 ~g of GBM (Fig. 2). 432  INTERACTION  BETWEEN  DNA,  COLLAGEN,  AND  GBM 
TABLE  I 
Binding of DNA  to GBM 
Radiolabeled prepara-  Origin  Bindings 
tions* 
% 
[3H]SSDNA  55.9 _+  Human fibroblasts  [3H]DSDNA  39.2 ± 
['25I]SSDNA  40.4 ± 
[,25I]DSDN  A  Calf thymus  50.7 _+ 
['25I]SSDNA  Mouse kidneys  31.2 ± 
['25I]SSDNA  Bacteria  36.3 ± 
(M. lysodeikticus) 
[~25I]SSDNA  Virus (SV40)  26.7 ± 
[~25I]SSDNA  Plant (tobacco)  44.8 _+ 
[125I]BSA  0.7 ± 
[1251]HGG  0.6 ± 
1.3§ 
6.0 
1.0 
2.1 
3.4 
4.9 
5.5 
0.9 
0.4 
0.3 
[51Cr]LPS  S. typhirnurium  1.4 -+ 0.7 
E. coli 0127:B8  1.9 +- 0.8 
E. coli 0111:B4  3.0 +- 0.6 
* 50 ng of radiolabeled  preparations was incubated with 300/~g of insoluble human 
GBM in the presence of 0.1 ml of 10% heat-inactivated NMS. 
$ Specific precipitation of radiolabeled  preparations with GBM. 
§ Mean of triplicates ± 1 SD. 
The  dissociation  rate  of  [125I]DNA-GBM  complexes  was  measured  in  the 
presence of an excess of unlabeled DNA. 50 ng of [125I]DNA was incubated with 
300 fig of GBM overnight at 4°C, then 50 ~g of unlabeled DNA was added. Tubes 
were taken at timed intervals thereafter. The percentage of [125I]DNA  bound to 
GBM was determined and compared to that of a control tube to which unlabeled 
DNA had  not  been  added.  In the  presence of unlabeled  SSDNA,  only 30%  of 
[~I]SSDNA was released from the  [~25I]SSDNA-GBM complexes after 12 h. In 
the  presence  of  unlabeled  DSDNA,  there  was  no  apparent  dissociation  of 
[12sI]SSDNA from GBM  (Fig.  3).  On the  other hand,  [~25I]DSDNA-GBM com- 
plexes were rapidly dissociated after the addition of unlabeled SSDNA as well as 
DSDNA. 
To find the optimal conditions under which DNA would be bound by GBM, the 
binding  activity  was  examined  at  various  temperatures,  pH values,  and  salt 
concentrations. The highest binding of [125I]SSDNA to GBM was observed at 4°C 
(36.5-+6.5%).  Less,  but  still  significant,  binding  was  seen  at  20°C  and  37°C, 
respectively  (25.2-+ 1.9  and  10.3-+ 1.9%).  A  maximal binding  of [125I]SSDNA  to 
GBM was observed between pH 7.0 and 9.0 and between 0.05 and 0.3 M NaC1. In 
the  presence  of an  anionic  detergent,  0.03%  sodium  dodecyl  sulfate  (SDS),  a 
strong inhibition of the binding of [~25I]SSDNA to GBM was also observed (with 
SDS:  2.0-+0.5%;  without SDS:  18.3-+2.7%). 
The relationship between the reaction  of DNA with  GBM and that of DNA 
with Clq  (30) was investigated.  Various amounts of purified human  Clq were 
added  to heat-inactivated  serum  and  incubated  with  [~25I]SSDNA  and  GBM. 
The binding  of [~25I]SSDNA to GBM was strongly inhibited by the addition  of r 
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Fro. I.  Inhibition  of the binding of [~251]DNA to GBM  by unlabeled DNA. Increasing 
amounts of  SSDNA  (©) and DSDNA  (@) were added to  a solution  of  100/~g of  GBM  which 
can fix specifically  about 30% of [~SI]DNA (5 ng).  (a) Percent inhibition  of  the binding of 
[~25I]SSDNA  to GBM  with unlabeled  DNA.  (b) Percent  inhibition of the binding of 
['25I]DSDNA. 
Clq and the inhibitory activity was dependent on the amount of Clq added to 
the reaction mixtures. This reaction may be responsible for the interference of 
fresh serum  with the binding of DNA  to  GBM.  Indeed,  when a  mixture of 
[~25I]SSDNA and GBM was incubated in the presence of fresh NMS, the binding 
of ['25I]SSDNA  was about two times lower than in the presence of heat-inacti- 
vated serum. 
To determine the participation of the collagen-like component of GBM (31) in 
the binding of DNA, GBM was treated with collagenase. In the conditions used, 
about 70% of GBM proteins, but less than 10% of [~25I]BSA, were digested. As 
compared with the undigested control, the binding of both types of DNA to GBM 
was almost completely abolished by the collagenase digestion of GBM (Table II). 
Most of [~25I]DNA could also be released from preformed [~25I]DNA-GBM com- 
plexes as a result of a  similar collagenase digestion. 
Binding  of DNA  to Collagen.  The possibility that DNA  could react with 
collagen molecules was investigated, using type I and type III collagen purified 
from bovine skin. 100 ~g of soluble and insoluble collagen was incubated with 10 
ng of [~25]SSDNA, [~25I]DSDNA, or [~SI]BSA in the presence of heat-inactivated 
NMS.  Significant amounts of [~25I]SSDNA and  [~25I]DSDNA were  bound  to 
soluble collagen as well as insoluble collagen, while [125I]BSA was not signifi- 
cantly precipitated (Table III). It was also found that DNA from other sources 
can bind collagen. 
The  DNA-binding  capacity of insoluble  GBM  and  collagen  (type  I)  were 
compared (Fig. 4).  At saturation, approximately 8 fig of SSDNA was bound to 
100 ~g of collagen, while 4 ~g of SSDNA was bound to 100  ~g of GBM. 434  INTERACTION  BETWEEN  DNA,  COLLAGEN,  AND  GBM 
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FIG.  2.  Binding curves of SSDNA  (©)  and DSDNA  (0)  to GBM.  Increasing amounts of 
SSDNA  and DSDNA were  incubated with  100  ~g of GBM,  The DNA-binding capacity of 
GBM is expressed on the vertical axis as weight ratio of DNA bound to GBM. 
Binding  of Preformed DNA-Anti-DNA  Complexes to  GBM.  Experiments 
were performed to determine whether or not anti-DNA antibodies could influ- 
ence the binding of DNA to GBM. First, the effect ofanti-DNA antibodies on the 
binding of [125I]DNA to GBM was examined. For this purpose,  two different 
antisera were used:  anti-SSDNA antibodies were obtained from mice immu- 
nized with DNA-mBSA complexes, and antibodies which were directed against 
both SSDNA and DSDNA were obtained from NZB × NZW F~ hybrid mice. 0.1 
ml of 10% heat-inactivated antisera was incubated with 50 ng of [125I]DNA at 4°C 
overnight, then 300 fig of GBM was added. As control, [125I]DNA was incubated 
with NMS. Antisera specific for SSDNA could specifically inhibit the binding of 
[~25I]SSDNA  but  not  that  of  [12~I]DSDNA (Table  IV).  On  the  other  hand, 
antisera which reacted with both DNAs could inhibit the binding of both types of 
[~25I]DNA to  GBM.  These  results  indicated that  anti-DNA  antibodies could 
interfere with the binding of DNA to GBM, presumably through the formation 
of immune complexes. 
Secondly,  to  see  the  effect  of  anti-DNA  antibodies  on  the  preformed 
[~25I]DNA-GBM  complexes,  the  following experiments  were  carried  out.  (a) 
[125I]SSDNA was incubated with anti-DNA antibodies overnight at 4°C,  then 
GBM was added, and the mixture was further incubated overnight at 4°C. (b) 
[125I]SSDNA,  antibodies,  and  GBM  were  incubated  simultaneously.  (c) 
[~2~I]SSDNA was first incubated with GBM, then antibodies were added. (d) As 
a control, [~25I]SSDNA and GBM were incubated with NMS. Table V shows the 
effect of anti-DNA antibodies on the binding of [125I]SSDNA to GBM. A strong 
inhibition of  the binding could be observed in experiment a, in which most of  the 
[125I]SSDNA  was  complexed  with  antibodies  before  the  reaction  with  GBM 
occurred. In experiment b, significant inhibition of the binding of [~25I]SSDNA 
was also seen.  However, in experiment c,  in which [~25I]SSDNA was already SHOZO  IZUI,  PAUL-HENRI  LAMBERT,  AND  PETER  A.  MIESCHER  435 
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FIG.  3.  Dissociation curves of [~25I]DNA-GBM complexes. [~25I]DNA (50  ng) was mixed 
with 300 ~tg of GBM overnight at 4°C, then 50 pg of unlabeled DNA was added, and after 1, 
2, 4, or 12 h, the percentage of [~25I]DNA bound to GBM was determined. As control, the 
same  procedures  were  used,  but  borate  buffer  was  added  to  the  mixtures instead  of 
unlabeled DNA. Solid line represents the percentage of control values of [~25I]SSDNA bound 
to  GBM  after the  addition  of unlabeled SSDNA  (O)  and  DSDNA  (0).  Interrupted line 
represents that  of [~25I]DSDNA  bound to  GBM  after the  addition  of unlabeled SSDNA 
(O- -  -O) and DSDNA (O- -  -O). 
TABLE  II 
Effect of Collagenase on Binding of DNA to GBM 
Treatment  [12~I]SSDNA ppt.*  ['25I]DSDNA ppt.* 
%  % 
GBM~;  22.4  _+ 4.611  21.8  _  6.2 
Collagenase-treated  2.3  _+  0.3  2.2  _+ 0.3 
GBM§ 
* 50 ng of '25I-labeled calf thymus DNA. 
$150 ~g of insoluble human GBM in 0.1 M Tris-acetate buffer. 
§ Incubated with 100 ftg of collagenase in 0.1 M Tris-acetate buffer for 12 h at 
37°C. 
[I  Mean of triplicates _1 SD. 
attached to GBM before the addition of antibodies, the antibodies did not have 
any dissociating effect on the [125I]SSDNA-GBM  complexes. 
Binding of Anti-DNA Antibodies to GBM-Bound DNA.  The previous find- 
ings suggested that DNA-anti-DNA complexes could not react efficiently with 
GBM, and raised the possibility that anti-DNA antibodies could react with DNA 
bound  to  GBM,  resulting  in  a  local  formation  of DNA-anti-DNA  immune 
complexes on GBM. 
To  investigate  this  possibility,  GBM  was  first  incubated  with  100  ~g  of 
SSDNA  or  DSDNA  overnight  at  4°C. After  incubation  and  washing,  anti- 
SSDNA antibodies or NMS were added and incubated overnight at 4°C. After 436  INTERACTION  BETWEEN  DNA,  COLLAGEN,  AND  GBM 
TABLE III 
Binding of DNA to Soluble and Insoluble Collagen 
Collagen  [125I]SSDNA  ppt.  [12~I]DSDNA  [~25I]BSA  ppt. 
ppt. 
%  %  % 
Calf skin (type I) 
Soluble*  68.2 _+ 0.1§  29.0 ± 0.9  3.2 ± 0.7 
Insoluble$  68.4 ±  1.6  23.4 _+ 6.9  1.8 ± 0.6 
Fetal calf skin (type III) 
Insoluble  82.3 ± 3.0  66.7 ± 2.8  0.1 ±  1.6 
* 10 ng of radiolabeled preparations was incubated with 100 ~g of soluble collagen in 
the presence of 10% heat-inactivated NMS at 37°C for 2 h. 
$100 ~g of insoluble collagen suspended in 0.1 ml of 0.15 M NaCl were incubated 
with 10 ng of radiolabeled preparations in the presence of 10% heat-inactivated 
NMS at 4°C overnight. 
§ Mean of triplicates ±1 SD. 
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FIG.  4.  Binding curves of SSDNA to GBM (©) and collagen (Q). Increasing amounts of 
SSDNA were incubated with 100/~g of GBM or collagen. The DNA-binding  capacity of these 
proteins is expressed on the vertical axis as weight ratio of DNA bound to GBM or collagen. 
washing, the mixtures were treated with DNase at 37°C for 12 h  to dissociate 
DNA-anti-DNA complexes.  The eluates obtained were tested for anti-SSDNA 
activity by  a  modification of the  Farr  test.  Eluates from  GBM-SSDNA-anti- 
SSDNA  mixtures  showed  a  significant SSDNA-binding activity  (Table  VI). 
Eluates from mixtures of GBM with anti-SSDNA serum without added SSDNA 
did not exhibit a  significant DNA-binding activity. A  similar experiment was 
performed using collagen instead of GBM and similar results were obtained. 
In  Vivo  Localization  of Injected  [125I]SSDNA  in  Kidneys.  The  previous 
experiments suggested that under certain circumstances, some DNA may bind 
to  GBM.  When  [125I]SSDNA  was  injected  intravenously to  normal  C57BL/6 SHOZO  IZUI,  PAUL-HENRI  LAMBERT,  AND  PETER  A.  MIESCHER 
TABLE  IV 
Binding of Preformed DNA-anti-DNA Complexes to GBM 
437 
Serum 
Serum DNA-binding activ- 
ity* 
Binding of DNA to GBM$ 
[125I]SSDNA  ['25I]DSDNA  [J2~I]SSDNA  [~25I]DSDNA 
%  % 
NMS  12.4  1.2  42.0  -+ 3.511  55.4  ±  6.0 
Anti-SSDNA§  65.6  2.4  4.5  ±  1.0  53.2  ±  4.4 
NZB/W sera  46.5  46.2  22.1  _+  2.9  29.0  ±  1.4 
* Serum ['25I]DNA binding activity was determined by the modified Farr test. 0.1 ml of 10% heat- 
inactivated sera was incubated with 50 ng of ['25I]DNA precipitated with 50% saturated ammo- 
nium sulfate. 
* 50 ng of [~25I]DNA was first incubated with 0.1 ml of 10% heat-inactivated antisera overnight at 
4°C, then 300 pg of GBM was added and incubated overnight at 4°C. 
§ Anti-SSDNA antisera  were obtained from  mice immunized with  DNA-mBSA complexes in 
Freund's incomplete adjuvant. 
II Mean of triplicates _1 SD. 
mice, a  small amount of DNA was still detected in kidneys after 2 and 8 days, 
but  this  binding  did  not  differ  significantly  from  that  of similarly  injecte  d 
[13~I]BSA. However, when this experiment was performed in mice which were 
injected with 100 ~g orS. typhimurium LPS (2 days before the injection of DNA 
or BSA), a very significant binding of DNA was observed in kidneys studied at 
48 h.  This ['~sI]SSDNA largely persisted in kidneys for several days as demon- 
strated  in  kidneys  studied  after  8  days  (Table  VII).  These  results  strikingly 
differ from  those  obtained  when  the  persistence  of injected  [~25I]SSDNA  was 
investigated on plasma samples.  Indeed,  no  [~25I]SSDNA could be detected in 
plasma 2 h  after the injection. 
Discussion 
The present data demonstrate that, in vitro, collagen and collagen-like struc- 
tures in GBM can bind DNA 40-80 times more than  HGG or BSA, and  10-40 
times more than LPS. This phenomenon appeared to be unrelated to the origin 
of the DNA tested since mammalian,  bacterial,  viral,  and plant DNA reacted 
similarly.  The fact that the digestion with collagenase almost completely abol- 
ished the binding of DNA, and that most of the bound DNA was released from a 
preformed [125I]DNA-GBM complex after treatment with collagenase, indicated 
that collagen was the DNA-binding protein in the preparations of collagen or of 
GBM which were studied.  One should note that the pretreatment of GBM with 
2.0  M  NaC1 or with  DNase,  to remove contaminating  histones  (29)  or DNA, 
resulted in an increase and not in a  decrease of the DNA-binding capacity. 
The previous observation of binding of DNA to Clq may reflect the particular 
affinity of collagen-containing  substances for DNA, since it is known that Clq 
contains collagen-like polypeptide chains (32) and is also affected by collagenase 
(33).  The  mechanism  of this  binding  is  probably  related  to  an  interaction 
between highly negatively charged DNA with the basic sites on collagen, GBM, 
or Clq. Such interaction actually occurs between DNA and other basic proteins 438  INTERACTION  BETWEEN  DNA~  COLLAGEN~  AND  GBM 
TABLE  V 
Effect of Anti-DNA Antibodies on Binding of DNA to GBM 
First reaction  Second reaction  ['~sI]SSDNA Inhibition 
with:  ppt. 
%  % 
[125I]SSDNA + Anti-DNA*  GBM$  16.8§  54.2 
['25I]SSDNA + Anti-DNA + GBM  (-)  28.0  23.7 
[12~I]SSDNA + GBM  Anti-DNA  36.4  0.8 
['25I]SSDNA + GBM + NMS  (-)  36.7  - 
* 50 ng of [125I]SSDNA was incubated with 0.1 ml of 10% heat-inactivated  anti- 
SSDNA  antisera.  Anti-SSDNA antisera  were  prepared  by  immunizing 
DNA-mBSA  complexes  in Freund's incomplete adjuvant in mice.  These 
antisera showed about 60% of [125I]SSDNA-binding  activity determined by 
the Farr test. 
300 ~g of GBM was suspended in 0.1 ml of 10% heat-inactivated NMS. 
§ Mean of duplicates. 
TABLE  VI 
Elution of Anti-DNA Antibodies from GBM-DNA-Anti-DNA 
Complexes 
[I~sI]SSDNA binding 
First reaction  Second reaction with:  activity of eluates* 
GBM + SSDNA$  Anti-SSDNA§  49.4 _+ 1.811 
GBM + DSDNA  Anti-SSDNA  17.7 -+ 0.5 
GBM + PBS  Anti-SSDNA  13.6 _+ 0.2 
GBM + SSDNA  NMS  13.8 -+ 0.3 
GBM + DSDNA  NMS  15.6 -+ 0.5 
GBM + PBS  NMS  17.9 +_ 0.8 
PBS + SSDNA  Anti-SSDNA  14.4 +_ 0.4 
* 0.025 ml of eluates was incubated with 10 ng of [~25I]SSDNA in the 
presence of 10% heat-inactivated NMS. [~sI]SSDNA-binding  activity 
was determined by the Farr test. 
$ 300  ~g of GBM was incubated with 100  ~g of SSDNA  or  DSDNA 
overnight at 4°C. 
§ 0.1 ml of heat-inactivated anti-SSDNA antisera obtained from mice 
immunized with DNA-mBSA complexes in Freund's incomplete adju- 
vant. 
II Mean of triplicates _+ 1 SD. 
such as histones, egg white lysozyme, mBSA (34, 35, 17). This type of interaction 
would also explain the  inhibiting effect of low pH,  low ionic strength, and of 
anionic detergents  such  as  SDS  on  the  DNA-binding capacity  of GBM.  The 
competitive effect of Clq on this binding may proceed through a  similar interac- 
tion. The interference with the binding of DNA by anti-DNA antibodies may 
result from a  change in the charge configuration of DNA after the binding of 
antibodies, although one cannot exclude the possibility that antibodies masked 
the binding site present in DNA or changed the spatial configuration  of DNA. 
The fact that 100 ~g of GBM can bind up to 4  ~g of SSDNA but only 0.5 ~g of 
DSDNA suggested a  higher affinity of GBM for SSDNA than for DSDNA. This SHOZO  IZUI,  PAUL-HENRI  LAMBERT,  AND  PETER  A.  MIESCHER  439 
TABLE  VII 
In Vivo Renal Localization of [~"~I]SSDNA  in Normal Mice and in LPS-Treated Mice 
Group*  Organ  [125I]SSDNA*  [~3q]BSA$ 
Normal  Kidneys  12.7 ± 4.~1  16.4 ± 3.3 
Liver  23.7 ± 5.7  22.0 ± 5.8 
Kidneys/liver  0.5 ± 0.1  0.8 ± 0.1 
LPS§  Kidneys  197.2 ± 45.8  12.5 ± 3.0 
Liver  23.2 ± 1.2  16.2 -+ 3,0 
Kidneys/liver  8.5 ± 1.8  0.8 ± 0.1 
* 8-wk-old C57BL/6 female mice (five mice in each group). 
5.0/zg of radiolabeled preparations was injected intravenously. 
§ 100 pg ofS. typhimurium  LPS was injected intraperitoneally at day 0. Radiolabeled prepara- 
tions were given at day 2. Mice were sacrificed at day 10. 
II Nanograms of injected radiolabeled preparations per gram of organ (mean -+ 1 SD). 
difference was  confirmed  in  dissociation  experiments  and  is  similar  to  that 
described for the interaction between DNA and mBSA  (17).  Moreover, inhibi- 
tion experiments indicated that unlabeled SSDNA was a strong inhibitor of the 
binding of [~2~I]DSDNA as well as [~I]SSDNA, whereas unlabeled DSDNA had 
a  strong  inhibitory  effect only on the  binding  of [~25I]DSDNA.  The  different 
binding properties of SSDNA and DSDNA may be due to the difference of charge 
density  in  their  secondary structures.  Although  some  [~25I]DSDNA  was  still 
bound by GBM after selective removal of most of the single-stranded  regions 
with  $1  nuclease,  one  cannot  exclude  that  single-stranded  regions  present 
within DSDNA (36) may be responsible for the binding of [~I]DSDNA to GBM. 
Alternatively, DNA may have two reactive sites for the binding to GBM.  One 
site  may  be  present  on  the  side  of the  basis,  exposed  only in  SSDNA,  and 
another  on  the  side  of the  backbone  which  is  exposed  in  both  SSDNA  and 
DSDNA. 
The biological significance of the high affinity of collagen and GBM for DNA 
should be considered in relation to the frequent tissue deposition of DNA-anti- 
DNA antibody complexes during the course of some human or animal diseases. 
Such  complexes have  been  found  in  GBM  (11,  13,  37),  epidermal  basement 
membrane (7,  14)  and in interstitial  tissues  (38), and their pathogenic signifi- 
cance has been demonstrated  (11, 37, 39, 40).  It is generally proposed that the 
tissue localization of DNA-anti-DNA complexes would result from the formation 
of such complexes in circulating blood with a secondary localization in filtering 
membranes  or  in  perivascular  areas  (41).  However,  although  immune  com- 
plexes are likely to exist in the plasma from patients with SLE, only occasional 
and  minute  amounts  of DNA-anti-DNA  complexes could  be  detected  in  the 
samples  (3). Furthermore, in rabbits and in mice it was found that DNA-anti- 
DNA  complexes  have  a  very short  half-life  in  circulating  blood  (42),  which 
should not favor their deposition in filtering membranes.  Since it was found in 
vitro: first, that DNA can be actively bound by collagen or GBM and, secondly, 
that DNA thus bound can act as an immunoabsorbant and react efficiently with 
free anti-DNA antibodies, one can imagine an alternative hypothesis to explain 
the  localization  of DNA-anti-DNA  complexes in  basement  membranes  or  in 440  INTERACTION  BETWEEN  DNA,  COLLAGEN,  AND  GBM 
interstitial  tissues.  Accordingly,  free  DNA  released  in  blood  (10,  43)  or  in 
extravascular  spaces  (44) from disrupted  autologous cells or from bacteria  or 
DNA viruses could, in a  first phase,  be bound by collagen fibers or basement 
membranes. When this occurs in an individual developing anti-DNA antibodies, 
DNA-anti-DNA complexes would easily be formed locally at the site of DNA 
localization without any requirement for circulating DNA-anti-DNA complexes. 
In  vivo,  some  factors  may  influence  the  binding  of DNA  by collagen-like 
substances.  Lower peripheral  temperatures,  increased vascular permeability, 
decrease  of blood DNase  activity and  decrease  of Clq level would favor this 
binding.  Some of these conditions are observed in patients with SLE (45) or in 
New Zealand mice (46). Our experimental data suggest that this may also occur 
in mice treated with LPS. Indeed, a  significant renal binding of injected DNA 
was observed in mice treated with LPS 2 days before this injection. Although the 
morphological distribution of this kidney-bound DNA has still to be defined, this 
phenomenon  may result  from  the  high  avidity  of GBM  structures  for  DNA. 
Furthermore,  it has been shown that in mice injected with LPS there is first a 
release of DNA in circulating blood and then an induction of anti-DNA antibod- 
ies (20). Recent observations indicate that these mice rapidly undergo a deposi- 
tion of immune complexes in renal glomeruli in which DNA-anti-DNA antibody 
complexes have been identified. 2 
Summary 
In vitro, collagen and collagen-like material  in GBM, were demonstrated to 
have  a  particular  high  affinity for  any  DNA tested  (mammalian,  bacterial, 
viral, and plant). GBM fixed DNA 40-80 times more than HGG and BSA and 10- 
40 times more than bacterial LPS. GBM has a higher affinity for SSDNA than 
for DSDNA. This binding was inhibited at low pH, low ionic strength, and in the 
presence of anionic  detergents,  indicating  that the highly negatively charged 
DNA may interact with the basic site on collagen or GBM by electrostatic forces. 
This  interaction  was  competitively interfered  with  by DNA-binding  proteins 
such as Clq. 
Complexes formed of DNA and anti-DNA antibodies did not exhibit the same 
binding  property  as free  DNA.  However,  DNA which  was  already  bound to 
GBM or to collagen could very efficiently bind anti°DNA antibodies and form 
immune complexes which would remain on these structures. 
Thebiological  significance  of the  binding  of DNA to  GBM  or  to  collagen 
should be particularly  considered in relation to the pathogenesis of SLE. It is 
possible that DNA released from disrupted or degenerating cells would bind to 
surrounding  collagen  fibers  or  to basement  membranes  and  then  act  as  an 
immunoabsorbant for circulating anti-DNA antibodies. Some evidence for an in 
vivo binding of SSDNA to renal structures was obtained in mice treated with 
bacterial LPS 2 days before the injection of SSDNA. 
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